We are pleased to announce that IBC will coordinate with our Pharmacy Services
department to facilitate Synagis? (palivizumab) for the 2011-2012 respiratory
syncytial virus (RSV) season, which is November through April in the United
States. RSV is the most common cause of bronchiolitis and pneumonia among
children younger than one year of age. During the RSV season, we will approve
the monthly administration of Synagis? (palivizumab) for at-risk children
younger than two years of age.
It is mandatory for all participating providers to obtain Synagis?
(palivizumab) through ACRO Pharmaceutical Services, an independent company. IBC
will coordinate with ACRO Pharmaceutical Services to facilitate delivery of
Synagis? (palivizumab) to your office.
If you have questions about the Synagis? (palivizumab) distribution program,
please contact Customer Service at 1-800-ASK-BLUE. Look for more information regarding
the shipment and facilitation of Synagis? (palivizumab) in next month?s edition
of Partners in Health Update.
Note: MedImmune, LLC, the makers of Synagis? (palivizumab), has a voluntary
program called RSV Connection?. However, IBC does not participate in this
program. All requests for Synagis? (palivizumab) should be sent directly to
ACRO Pharmaceutical Services.